MX2021015338A - Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma. - Google Patents

Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma.

Info

Publication number
MX2021015338A
MX2021015338A MX2021015338A MX2021015338A MX2021015338A MX 2021015338 A MX2021015338 A MX 2021015338A MX 2021015338 A MX2021015338 A MX 2021015338A MX 2021015338 A MX2021015338 A MX 2021015338A MX 2021015338 A MX2021015338 A MX 2021015338A
Authority
MX
Mexico
Prior art keywords
pridopidine
symptoms
analog
composition
huntington disease
Prior art date
Application number
MX2021015338A
Other languages
English (en)
Inventor
Michal Geva
Michael Hayden
Elena Berelovich
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/438,508 external-priority patent/US11090297B2/en
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Publication of MX2021015338A publication Critical patent/MX2021015338A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se dirige a un método de tratamiento de un paciente humano afectado por la enfermedad de Huntington y/o síntomas de la misma, que comprende la administración al paciente de una composición farmacéutica que comprende pridopidina o una sal farmacéuticamente aceptable de la misma y un análogo de la misma o una sal farmacéuticamente aceptable de la misma.
MX2021015338A 2019-06-12 2020-06-12 Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma. MX2021015338A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/438,508 US11090297B2 (en) 2013-06-21 2019-06-12 Pridopidine for treating huntington's disease
PCT/IL2020/050654 WO2020250234A1 (en) 2019-06-12 2020-06-12 Composition comprising pridopidine and analog thereof for treating huntington disease and symptoms thereof

Publications (1)

Publication Number Publication Date
MX2021015338A true MX2021015338A (es) 2022-01-18

Family

ID=73782137

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015338A MX2021015338A (es) 2019-06-12 2020-06-12 Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma.

Country Status (11)

Country Link
EP (1) EP3982963A4 (es)
JP (2) JP7436524B2 (es)
CN (1) CN113950328A (es)
AU (1) AU2020293739B2 (es)
BR (1) BR112021024744A2 (es)
CA (1) CA3137633A1 (es)
CL (1) CL2021003312A1 (es)
EA (1) EA202193190A1 (es)
IL (1) IL288940A (es)
MX (1) MX2021015338A (es)
WO (1) WO2020250234A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021366505A1 (en) * 2020-10-20 2023-06-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine and analogs for the treatment of anxiety and depression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
MX347209B (es) * 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
EA201590655A8 (ru) * 2012-09-27 2016-07-29 Тева Фармасьютикал Индастриз Лтд. Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
SG11201509729YA (en) * 2013-06-21 2015-12-30 Teva Pharmaceuticals Int Gmbh Use of high dose pridopidine for treating huntington's disease
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
IL311081A (en) * 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline

Also Published As

Publication number Publication date
JP2024016113A (ja) 2024-02-06
CN113950328A (zh) 2022-01-18
IL288940A (en) 2022-02-01
EP3982963A4 (en) 2023-06-21
EP3982963A1 (en) 2022-04-20
CL2021003312A1 (es) 2022-08-26
WO2020250234A1 (en) 2020-12-17
JP7436524B2 (ja) 2024-02-21
JP2022535929A (ja) 2022-08-10
BR112021024744A2 (pt) 2022-03-22
AU2020293739B2 (en) 2023-11-30
EA202193190A1 (ru) 2022-03-24
CA3137633A1 (en) 2020-12-17
AU2020293739A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
MX2019012884A (es) Terapia de combinacion.
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX368387B (es) A22k, desb27, b29r, des b30 en la posicion epsilon del analogo de insulina humana acilada de lisina 22.
EP4324521A3 (en) Treatment of fabry disease in ert-naive and ert-experienced patients
MX2016009231A (es) Administracion de tasimelteon en condiciones de ayuno.
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
AU2018326364A1 (en) Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease
AR119159A1 (es) Tratamientos de angioedema
MX2021011269A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
MX2021002322A (es) Nuevos metodos.
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2021015338A (es) Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma.
MY193963A (en) Composition for treating joint diseases and kit containing same
EP3919052A4 (en) PHARMACEUTICAL COMPOSITION FOR INTRAOCULAR OR ORAL ADMINISTRATION FOR THE TREATMENT OF RETINAR DISEASES
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
MX2019004200A (es) Terapia de combinacion.
EA202090416A1 (ru) Способы лечения симптомов гастропареза с использованием велусетрага
MX2021011183A (es) Fitoecdisonas y los derivados de las mismas para su uso en el tratamiento de la alteracion de la funcion respiratoria.
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
EA202193276A1 (ru) Способы лечения холангиокарциномы
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제